CELL: Zika vaccination may have protective effect on infection with new coronavirus in elderly (ACTIVATE trial)

The pandemic of the new coronavirus, also known as COVID-19, is seriously affecting the health of the global population and the economies of countries around the world.
many countries are under blockade and one third of the world's population is in some form of movement restriction, which has serious financial and social implications.
urgent need to reverse this situation can only be achieved by producing immune shields to protect the population from SARS-CoV-2 infection.
countries are currently making many efforts to develop a new crown vaccine, but it is likely to take at least 12 to 24 months to develop an effective vaccine.
children can prevent heterogeneic infections and improve survival rates, and this is not related to the prevention of tuberculosis.
, researchers reported the results of a three-part ACTATE trial in the journal CELL.
the trial assessed whether the card seedling had a similar effect on the elderly.
in this double-blind, randomized trial, elderly patients (n-198) were vaccinated against card-mediated seedlings or placebos upon discharge from the hospital and followed up for 12 months to see if there were any new infections.
the interim analysis showed a significant increase in the time of first infection (median 16 weeks compared to 11 weeks after placebo).
42.3% (95% CIs 31.9-53.4%) after placebo vaccination and 25.0 after vaccination % (95% CIs 16.4-36.16%);
, and in the trial, there was no significant difference in the frequency of adverse reactions between the two groups of subjects.
, these data show that vaccination cards are safe and can protect older people from infection.
results also require larger studies to assess the protection of card-based seedlings against respiratory infections, including COVID-19 infections.
.